KITE Kite Pharma, Inc.

81.15
+2  (2%)
Previous Close 79.55
Open 79.90
Price To book 9.31
Market Cap 4.07B
Shares 50,190,000
Volume 904,636
Short Ratio 3.79
Av. Daily Volume 1,582,590

SEC filingsSee all SEC filings

  1. 8-K - Current report 17758590
  2. 8-K - Current report 17694994
  3. 8-K - Current report 17668812
  4. 424B5 - Prospectus (Rule 424(b)(5)) 17668773
  5. 424B5 - Prospectus (Rule 424(b)(5)) 17656882

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiated October 2016. Phase 1 data due 2017.
KTE-C19 (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 2 pivotal initiated November 2015. Data due 2018.
KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 data due 2018.
KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 2 data due 2018.
KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
Phase 2 pivotal top-line data released September 26, 2016. Primary analysis released February 28, 2017 showed trial met primary endpoint. Rolling BLA filing initiated December 2016 with completion expected 1Q 2017.
Axicabtagene ciloleucel (KTE-C19) - ZUMA-1
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer

Latest News

  1. If You're in Your 30s, You Should Consider Buying These Stocks
  2. Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps
  3. The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)
  4. Cramer's charts show these biotechs ignoring their 'polit...
  5. The First CAR-T Drugs Have Left the Gate
  6. Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards
  7. Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait
  8. Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug
  9. Kite Presents Promising Preclinical Data from KITE-585, a Fully Human Anti-BCMA CAR T-Cell Product Candidate at the 2017 American Association of Cancer Research (AACR) Annual Meeting
  10. Kite Highlights Publication on Breakthrough in Generating Fully Functioning T Cells from Hematopoietic Precursor Cells by Leading Researchers at the University of California, Los Angeles (UCLA)
  11. Snap Started At Hold, Kite Pharma Can't Stay Aloft, Accenture Cut
  12. Kite Pharma Completes Filing for CAR-T Therapy with FDA
  13. Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting
  14. Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)
  15. Novartis' CTL109 BLA Gets Priority Review Status from FDA
  16. Amgen's Blincyto sBLA Secures FDA Priority Review
  17. Novartis' Leukemia Drug Secures Priority Review
  18. Kite to Present Two Plenary Presentations from the ZUMA-1 Pivotal Trial of Axicabtagene Ciloleucel at the 2017 American Association of Cancer Research Annual Meeting
  19. Novartis Makes Plans For Its Cancer-Killing T Cells
  20. Better Buy: Bellicum Pharmaceuticals, Inc. vs. Kite Pharma